添加的内容 删除的内容
(我来啦, replaced: 財 → 财, 併 → 并) |
小 (机器人:清理不当的来源、移除无用的模板参数) |
||
(未显示2个用户的4个中间版本) | |||
第13行: | 第13行: | ||
| industry = [[生物技术]] |
| industry = [[生物技术]] |
||
| products = [[Epogen]]、[[Neulasta]]、[[Neupogen]]等 |
| products = [[Epogen]]、[[Neulasta]]、[[Neupogen]]等 |
||
| revenue = {{Increase}} [[美元|US$]] 200.63亿(2014)<ref name="2014-10-K">{{cite web |url=https://www.sec.gov/Archives/edgar/data/318154/000031815415000005/amgn-12312014x10k.htm |title=Amgen Inc., Form 10-K, Annual Report, For the Fiscal Year Ended December 31, 2014, Filing Date Feb 19, 2015 |publisher=Securities and Exchange Commission |accessdate=2015-03-27 |
| revenue = {{Increase}} [[美元|US$]] 200.63亿(2014)<ref name="2014-10-K">{{cite web |url=https://www.sec.gov/Archives/edgar/data/318154/000031815415000005/amgn-12312014x10k.htm |title=Amgen Inc., Form 10-K, Annual Report, For the Fiscal Year Ended December 31, 2014, Filing Date Feb 19, 2015 |publisher=Securities and Exchange Commission |accessdate=2015-03-27 }}</ref> |
||
| operating_income = {{Increase}} US$ 61.91亿(2014)<ref name="2014-10-K"/> |
| operating_income = {{Increase}} US$ 61.91亿(2014)<ref name="2014-10-K"/> |
||
| net_income = {{Increase}} US$ 51.58亿(2014)<ref name="2014-10-K"/> |
| net_income = {{Increase}} US$ 51.58亿(2014)<ref name="2014-10-K"/> |
||
第21行: | 第21行: | ||
| homepage = {{URL|www.amgen.com}} |
| homepage = {{URL|www.amgen.com}} |
||
}} |
}} |
||
'''安进'''('''AMGen''',原称'''A'''pplied '''M'''olecular '''Gen'''etics)是一家美国制葯公司,总部位于加州[[千橡市 (加利福尼亚州)|千橡市]]。它成立于1980年, |
'''安进'''('''AMGen''',原称'''A'''pplied '''M'''olecular '''Gen'''etics)是一家美国制葯公司,总部位于加州[[千橡市 (加利福尼亚州)|千橡市]]。它成立于1980年,经过多次兼并,成为世界最大的制葯公司之一<ref>{{Cite web|url=https://www.fiercepharma.com/special-report/top-15-pharma-companies-by-2018-revenue|title=The top 15 pharma companies by 2018 revenue|date=2019-08-08|publisher=Fierce Pharma|access-date=2019-09-27}}</ref>。 |
||
== 历史 == |
== 历史 == |
||
2019年8月,安进宣布计 |
2019年8月,安进宣布计划斥资134亿美元收购[[赛尔基因]]的银屑病治疗药物[[阿普斯特]](Apremilast,Otezla),算上22亿美元的稅务得益,实际交易額约为112亿美元。<ref>{{Cite web |url=https://ctee.com.tw/news/biotech/137442.html |title=安进以134亿美元收购药品Otezla 股价同乐 |date=2019-08-27 |access-date=2019-09-25 }}</ref> |
||
2019年11月1日安进斥资27亿美元认购[[百 |
2019年11月1日安进斥资27亿美元认购[[百济神州]]已发行股本的20.5%。 |
||
== 参考文献 == |
== 参考文献 == |
||
第33行: | 第33行: | ||
* [http://www.amgen.com/ Official website] |
* [http://www.amgen.com/ Official website] |
||
* [http://www.secdatabase.com/CIK/318154/Company-Name/AMGEN-INC Amgen SEC Filings] |
* [http://www.secdatabase.com/CIK/318154/Company-Name/AMGEN-INC Amgen SEC Filings] |
||
* |
* Amgen Inc. Company Profile Profile at Google Finance. |
||
* [ |
* [http://investing.businessweek.com/research/stocks/snapshot/snapshot.asp?ticker=AMGN:US Businessweek.com] |
||
{{NASDAQ-100}} |
{{NASDAQ-100}} |
||
[[Category:美国制 |
[[Category:美国制药公司]] |
||
[[Category:1980年成立的公司]] |
[[Category:1980年成立的公司]] |
||
[[Category:标 |
[[Category:标准普尔500指数成分股]] |
||
[[Category:财富500强公司]] |
[[Category:财富500强公司]] |